Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-061440
Filing Date
2025-05-01
Accepted
2025-05-01 07:05:22
Documents
65
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q phat-20250331.htm   iXBRL 10-Q 1882046
2 EX-10.1 phat-ex10_1.htm EX-10.1 142333
3 EX-10.2 phat-ex10_2.htm EX-10.2 109650
4 EX-31.1 phat-ex31_1.htm EX-31.1 15611
5 EX-31.2 phat-ex31_2.htm EX-31.2 15666
6 EX-32.1 phat-ex32_1.htm EX-32.1 9623
7 EX-32.2 phat-ex32_2.htm EX-32.2 9650
  Complete submission text file 0000950170-25-061440.txt   9236622

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT phat-20250331.xsd EX-101.SCH 1691043
68 EXTRACTED XBRL INSTANCE DOCUMENT phat-20250331_htm.xml XML 1338597
Mailing Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932 (877) 742-8466
Phathom Pharmaceuticals, Inc. (Filer) CIK: 0001783183 (see all company filings)

EIN.: 824151574 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39094 | Film No.: 25899360
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)